EUVIMEDEUVIMED entdecken
Crossref

Rational Design and Identification of ISM7594 as a Tissue-Agnostic FGFR2/3 Inhibitor

Yazhou Wang, Jinxin Liu, Yihong Zhang, Jichen Zhao, Chao Wang, Hui Cui, Fanye Meng, Alex Aliper iD, Tao Liang, Feng Yan, Feng Ren iD, Jiong Lan und 5 weitere

Journal of Medicinal Chemistry · 2025

DOI: 10.1021/acs.jmedchem.5c00928 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Yazhou Wang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Insilico Medicine Shanghai Ltd, Suite 901 Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 3, Receptor, Fibroblast Growth Factor, Type 2, Drug Design, Antineoplastic Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 56 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The selective inhibition of fibroblast growth factor receptors (FGFR) presents a significant challenge due to the high degree of sequence and the close structural similarity of the subtypes. Herein, we designed selective dual FGFR2/3 inhibitors based on the in-depth understanding of protein-ligand interaction contributions. We efficiently identified ISM7594 (4) with distinctive flexible hinge binder and a unique central core that potently inhibited FGFR2/3 and selectively spared FGFR1/4. The "magic methyl" effect played a crucial role in enhancing the activity. ISM7594 maintained strong activity against multiple FGFR2/3 mutants known to drive resistance to current drugs and broad-spectrum antiproliferative potency in cancer cells harboring diverse FGFR2/3 alterations, including FGFR2/3 amplification, fusion, and mutation types. The compound demonstrated robust tumor growth suppression, favorable pharmacokinetic profile, and pharmacodynamic effects. This study supports the preclinical development of ISM7594 and demonstrates its potential in advancing tissue-agnostic therapy for advanced solid tumors with FGFR2/3 aberrations and mutation resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptor, Fibroblast Growth Factor, Type 3Receptor, Fibroblast Growth Factor, Type 2Drug DesignAntineoplastic AgentsProtein Kinase InhibitorsHumansAnimalsCell Line, TumorStructure-Activity RelationshipMiceCell ProliferationMice, NudeMutation

Substanzen

Receptor, Fibroblast Growth Factor, Type 3Receptor, Fibroblast Growth Factor, Type 2FGFR3 protein, humanAntineoplastic AgentsFGFR2 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Insilico Medicine Shanghai Ltd, Suite 901 Tower C, Changtai Plaza, 2889 Jinke Road, Pudong New District, Shanghai 201203, China.
  • GenFleet Therapeutics (Shanghai) Inc., Shanghai 201203, China.
  • Insilico Medicine AI Limited, Masdar City, Abu Dhabi 145748, UAE.

ORCID-Profile: Alex Aliper, Feng Ren, Fusheng Zhou, Xiao Ding, Alex Zhavoronkov

Zitieren

APA

Wang, Y., Liu, J., Zhang, Y., Zhao, J., Wang, C., Cui, H., Meng, F., Aliper, A., Liang, T., Yan, F., Ren, F., Lan, J., Lu, Q., Zhou, F., Cai, X., Ding, X., & Zhavoronkov, A. (2025). Rational Design and Identification of ISM7594 as a Tissue-Agnostic FGFR2/3 Inhibitor. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c00928

Vancouver

Wang Y, Liu J, Zhang Y, Zhao J, Wang C, Cui H, et al. Rational Design and Identification of ISM7594 as a Tissue-Agnostic FGFR2/3 Inhibitor. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.5c00928

BibTeX
@article{Wang2025,
  author = {Wang, Yazhou and Liu, Jinxin and Zhang, Yihong and Zhao, Jichen and Wang, Chao and Cui, Hui and Meng, Fanye and Aliper, Alex and Liang, Tao and Yan, Feng and Ren, Feng and Lan, Jiong and Lu, Qiang and Zhou, Fusheng and Cai, Xin and Ding, Xiao and Zhavoronkov, Alex},
  title = {Rational Design and Identification of ISM7594 as a Tissue-Agnostic FGFR2/3 Inhibitor},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  doi = {10.1021/acs.jmedchem.5c00928}
}
Kostenlos starten →